Tag: CYRN

Blue Horseshoe Stocks: ACRX, DSCO & More

Tesla Motors, Inc. TSLA – Options

Yesterday, those of our readers following our recent coverage of TSLA were once again presented with opportunities coming out of the 05/22 $230-240 Calls that we’ve been monitoring since Friday. TSLA registered a higher high and a higher low for the fifth consecutive session, topping out at 248.30. As a result, the total possible gains on our initial calls were pushed even further into the green, so we wanted to provide an update on those figures:

$230 Calls  – Friday’s Low: 6.85 – Yesterday’s High: 17.95 – Max Gain: 162%

$232.50 Calls  – Friday’s Low: 5.32 – Yesterday’s High: 16.90 – Max Gain: 217%

$235 Calls  – Friday’s Low: 5.96 – Yesterday’s High: 13.95 – Max Gain: 134%

$237.50 Calls  – Friday’s Low: 3.16 – Yesterday’s High: 12.00  – Max Gain: 280%

$240 Calls  – Friday’s Low: 3.84 – Yesterday’s High: 10.50 – Max Gain: 173%

These moves are a perfect example of what draws us to options trading; with just a 6% increase in TSLA stock, we’ve witnessed huge gains across the board in the options chain. These contracts don’t expire until next Friday, so we’ll keep our fingers on TSLA’s pulse until that time.

AcelRx Pharmaceuticals, Inc. ACRX

Popping up on our scanner this morning is a play that has both an interesting chart as well as a blockbuster PR out today that is leading to a gap-up in premarket trading (3.30-3.80’s).

We’re catching the stock as it comes up off of a relative bottom, and as we point out on the snapshot below, there are several attractive features of the current ACRX chart.

Couple that with this morning’s revelation of a contract the company has struck with the US Dept. of Defense, and ACRX becomes instantly worthy of our attention as the week draws to a close.

Discovery Laboratories, Inc. DSCO

Speaking of pharma stocks with fresh news, DCSO is also cropping up on our scanner this morning. Like the aforementioned play, this morning/s PR is resulting in a gap-up, and we’ll want to have our eyes peeled for potential advantageous activity on the chart once the session commences.

According to the release, Phase II testing of its AEROSURF® product has yielded “encouraging safety and physiological data suggest that aerosolized KL4 surfactant can be delivered to the lung of premature infants with respiratory distress syndrome”

Extended Watchlist:
PTBI, CYRN, BAA, CDTI, WOGI

Blue Horseshoe Stocks: ARNA Recap & More

Arena Pharmaceuticals, Inc. ARNA

You have to go a long way back to find our very first coverage of ARNA. It was May 11th, 2012 that we first mentioned this stock as an item to have on long-term watch. At that time the company had an obesity treatment that was awaiting FDA approval.

The public sentiment during that summer was that FDA approval was all but in the bag, and as we waited the stock began a monstrous run from a low of 5.44 to the day of its approval when it hit 13.50, an overall increase of 148% It would be a very long time before we talked about ARNA again.

The next time was fairly recently on November 3rd when we included ARNA on our Extended Watchlist, and over a period of a few sessions, saw the stock make a decent move from a low of 4.12 to 4.76. After that, it endured a series of incremental pullbacks over the next several weeks.

Yesterday morning, in a stroke of superb timing we tagged the stock in our watchlist once again, and what it did next blew the run we witnessed in November right out of the water!  Coinciding with the announcement of positive top-line results on another of the company’s treatments (this one for autoimmune disease) ARNA made a huge intraday run from a low of 3.66 to all the way up to 6.09. That’s a hefty 66% increase in a single session, and it came on approximately 20X the 3-month average volume, so cheers are in order for anyone who took advantage of our timely alert!

Heritage Media Corp. HMCP

Since we mentioned HMCP for the first time on New Year’s Eve, the stock has provided us with a few quality swing-trade opportunities. That day the stock traded in a range from .0047 to .0068, an intraday gain of 45% In following sessions we then observed subsequent swings from .0037-.0064 (+73%) and .0034-.0062 (+82%) making HMCP a flipper’s dream.

As we point out on the snapshot below, what has formed on the chart is known as a bullish flag, which is known to be a signal of further gains. Couple that with an RSI that’s screaming toward the power zone, and it makes HMCP one that we’ll really need to watch closely as we head into week’s end.

Extended Watchlist:
BIND, BIOD, FOLD, NRX, CYRN, AVEO, ACUR, PLX, S

Blue Horseshoe Stocks: ABIO Recap & More

ARCA BioPharma, Inc. ABIO

Our top performer from yesterday’s report was most assuredly ABIO. We tagged this play after noticing that it had announced being granted orphan drug status by the FDA for “rNAPc2” as a potential treatment of viral hemorrhagic fever post-exposure to the Ebola virus.

Fresh FDA-related plays can often provide a healthy move to take advantage of, and that’s just what we got from ABIO, The stock traded in a range from .82-1.03, an intraday increase of 25% on nearly ten times the 3-month average volume.

Our long-time readers might recall our coverage of this stock last year in December, which sort of got lost in the shuffle that was the hysteria created by the “Green Rush”. We tracked the stock from the low 1.40’s to over 2.20 over a period of a few weeks, so it will be interesting to see if history continues to repeat itself with ABIO, especially with the stock coming off of it 52-week low on Tuesday.

CYREN Ltd. CYRN

We also wanted to acknowledge the early morning move made by another of the stocks we mentioned in yesterday’s newsletter, CYRN. It bolted out of the gate, quickly running from 2.22 to 2.67, a 20% spike within the first 15 minutes of the session.

The stock got hammered into the close quite a bit, so we’ll be open to the possibility of seeing some bounce action, provided it can hold support at or above the 50DMA of 1.75.

Office Depot, Inc. ODP

ODP is in the midst of making a big move on the heels of large activist investor Starboard Value taking up a position which equates to 6% of ODP’s total shares. It also upped its stake in Staples to 10% fueling speculation that it could create pressure for the two office supply giants to merge. It will definitely be a story that we’ll be interested to follow moving forward.

Extended Watchlist:
GPT, RGDX, CYTX, DRD